Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DAVID W VICTOR

Allopathic & Osteopathic Physicians Internal Medicine Transplant Hepatology

NPI
1508048919
CMS profile
295200
Location
HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$105,728.51

114 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DAVID W VICTOR

NPI 1508048919 · CMS profile ID 295200

Allopathic & Osteopathic Physicians / Internal Medicine / Transplant Hepatology

HOUSTON, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1508048919?year=2025&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DAVID W VICTOR, NPI 1508048919, CMS profile ID 295200. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1508048919?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). DAVID W VICTOR, NPI 1508048919, CMS profile ID 295200. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1508048919?year=2025&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
DAVID W VICTOR, NPI 1508048919, CMS profile ID 295200, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–114 of 114 matching records. This page contains 14 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1508048919?year=2025&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

114 matching records · $105,728.51 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 114 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–114 of 114.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Madrigal Pharmaceuticals $15.8802/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248319856 CMS
Eisai Inc. $32.5702/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244475813 CMS
Ipsen Biopharmaceuticals, Inc $299.1202/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208842957 CMS
Ipsen Biopharmaceuticals, Inc $8,835.7502/08/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1208842959 CMS
Ipsen Biopharmaceuticals, Inc $129.9702/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1208842961 CMS
Ipsen Biopharmaceuticals, Inc $441.1502/08/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1208842963 CMS
La Jolla Pharmaceutical Company $30.2902/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1237497293 CMS
Madrigal Pharmaceuticals $147.4901/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248319852 CMS
Madrigal Pharmaceuticals $3,878.0001/27/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248319854 CMS
Madrigal Pharmaceuticals $2,115.0001/17/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1248319850 CMS
Intra-Sana Laboratories $17.6101/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251425154 CMS
Mallinckrodt Hospital Products Inc. $27.6301/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1212005993 CMS
Madrigal Pharmaceuticals $14.8401/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248319848 CMS
Intercept Pharmaceuticals, Inc. $23.6501/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1249870358 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $29,693.29 76
PY2020 $13,204.92 41
PY2021 $10,303.33 44
PY2022 $16,147.00 42
PY2023 $17,231.45 52
PY2024 $56,918.92 68
PY2025 $105,728.51 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $98,366.68 53
PY2024 Principal investigator $112,834.49 31
PY2023 Principal investigator $70,322.99 25
PY2022 Recipient $121.01 2
PY2022 Principal investigator $181,099.82 25
PY2021 Principal investigator $67,565.94 40
PY2020 Principal investigator $218,135.68 12
PY2019 Recipient $12,900.00 3
PY2019 Principal investigator $317,339.92 41

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

53 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Bioscience Inc. $81.60 12/30/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545087
Principal investigator 1 Madrigal Pharmaceuticals $550.00 12/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254562
Principal investigator 1 Madrigal Pharmaceuticals $1,950.00 12/19/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254567
Principal investigator 1 Ipsen Bioscience Inc. $1,625.00 12/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545085
Principal investigator 1 Ipsen Bioscience Inc. $421.00 12/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545089
Principal investigator 1 Madrigal Pharmaceuticals $539.50 12/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253998
Principal investigator 1 Madrigal Pharmaceuticals $390.00 12/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254002
Principal investigator 1 Madrigal Pharmaceuticals $450.00 12/11/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248254005
Principal investigator 1 Madrigal Pharmaceuticals $4,398.63 12/04/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248253498
Principal investigator 1 Ipsen Bioscience Inc. $90.00 12/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546397
Principal investigator 1 Madrigal Pharmaceuticals $2,363.32 11/07/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248252520
Principal investigator 1 Ipsen Bioscience Inc. $90.00 11/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546395
Principal investigator 1 Madrigal Pharmaceuticals $9,853.86 10/23/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248251972
Principal investigator 1 Ipsen Bioscience Inc. $90.00 10/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546393
Principal investigator 1 Madrigal Pharmaceuticals $4,549.85 09/23/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250648
Principal investigator 1 Madrigal Pharmaceuticals $450.00 09/23/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250652
Principal investigator 1 Madrigal Pharmaceuticals $550.00 09/23/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248250656
Principal investigator 1 Ipsen Bioscience Inc. $90.00 09/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546391
Principal investigator 1 Ipsen Bioscience Inc. $5,205.50 08/07/2025 Non-covered Recipient Entity
Medical College Of Wisconsin
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545563
Principal investigator 1 Ipsen Bioscience Inc. $1,300.00 08/07/2025 Non-covered Recipient Entity
Medical College Of Wisconsin
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545565
Principal investigator 1 Madrigal Pharmaceuticals $2,035.31 08/07/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248248207
Principal investigator 1 Ipsen Bioscience Inc. $90.00 08/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546389
Principal investigator 1 Madrigal Pharmaceuticals $550.00 07/31/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248247930
Principal investigator 1 Ipsen Bioscience Inc. $90.00 07/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546387
Principal investigator 1 Madrigal Pharmaceuticals $2,646.88 06/24/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246093
Principal investigator 1 Madrigal Pharmaceuticals $9,853.86 06/24/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246097
Principal investigator 1 Madrigal Pharmaceuticals $390.00 06/24/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246101
Principal investigator 1 Madrigal Pharmaceuticals $1,950.00 06/24/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248246105
Principal investigator 1 Madrigal Pharmaceuticals $2,514.54 06/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244977
Principal investigator 1 Madrigal Pharmaceuticals $195.00 06/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244981
Principal investigator 1 Madrigal Pharmaceuticals $1,950.00 06/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244985
Principal investigator 1 Madrigal Pharmaceuticals $450.00 06/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244990
Principal investigator 1 Madrigal Pharmaceuticals $4,165.06 06/05/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244994
Principal investigator 1 Ipsen Bioscience Inc. $90.00 06/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546385
Principal investigator 1 Madrigal Pharmaceuticals $2,296.44 05/28/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248244652
Principal investigator 1 Madrigal Pharmaceuticals $2,514.54 05/15/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248243791
Principal investigator 1 Ipsen Bioscience Inc. $90.00 05/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546383
Principal investigator 1 Madrigal Pharmaceuticals $1,417.00 04/10/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242105
Principal investigator 1 Madrigal Pharmaceuticals $1,950.00 04/10/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242109
Principal investigator 1 Madrigal Pharmaceuticals $390.00 04/10/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248242114
Principal investigator 1 Madrigal Pharmaceuticals $2,296.44 04/08/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248241820
Principal investigator 1 Ipsen Bioscience Inc. $90.00 04/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546381
Principal investigator 1 Madrigal Pharmaceuticals $3,095.63 03/13/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240980
Principal investigator 1 Madrigal Pharmaceuticals $2,296.44 03/06/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248240599
Principal investigator 1 Ipsen Bioscience Inc. $90.00 03/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546379
Principal investigator 1 Madrigal Pharmaceuticals $4,549.85 02/06/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248239419
Principal investigator 1 Ipsen Bioscience Inc. $90.00 02/01/2025 Non-covered Recipient Entity
Houston Methodist Hospital Skilled Nursing Facility
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176546377
Principal investigator 1 Ipsen Bioscience Inc. $1,300.00 01/29/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545081
Principal investigator 1 Madrigal Pharmaceuticals $9,006.43 01/16/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) No dispute reported 06/30/2026 1248238483
Principal investigator 1 Bausch Health US, LLC $1,820.00 01/10/2025 Non-covered Recipient Entity
Methodist Hospital Research Institute
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843395
Principal investigator 1 Bausch Health US, LLC $2,000.00 01/10/2025 Non-covered Recipient Entity
Methodist Hospital Research Institute
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843400
Principal investigator 1 Bausch Health US, LLC $975.00 01/10/2025 Non-covered Recipient Entity
Methodist Hospital Research Institute
Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis (RED-C-3132) No dispute reported 06/30/2026 1224843405
Principal investigator 1 Ipsen Bioscience Inc. $90.00 01/01/2025 Non-covered Recipient Entity
THE METHODIST HOSPITAL RESEARCH INSTITUTE
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid No dispute reported 06/30/2026 1176545083